A 48-year-old woman from Mumbai with a 15-year history of poorly controlled type 2 diabetes (HbA1c 9.1%) and obesity (BMI 34 kg/m²) presents for lipid management. She is currently on metformin and glibenclamide. Fasting lipid panel shows: total cholesterol 310 mg/dL, LDL-C 220 mg/dL, HDL-C 28 mg/dL, triglycerides 480 mg/dL. She is started on atorvastatin 80 mg daily. After 8 weeks of therapy with good adherence, LDL-C falls to 140 mg/dL, but triglycerides remain elevated at 420 mg/dL. Liver function tests and creatinine kinase are normal. Which of the following best explains the persistent hypertriglyceridaemia despite statin monotherapy in this patient?

Explanation

## Statin Monotherapy and Residual Hypertriglyceridaemia in Insulin Resistance ### Pathophysiology of Triglyceride Elevation in Diabetes **Key Point:** Hypertriglyceridaemia in type 2 diabetes is primarily driven by **increased hepatic VLDL synthesis**, not impaired clearance. This occurs because: 1. Insulin resistance → reduced hepatic lipogenesis inhibition 2. Increased hepatic fatty acid uptake from adipose tissue (elevated FFA) 3. Enhanced hepatic triglyceride synthesis and VLDL assembly **High-Yield:** Statins primarily target LDL metabolism through HMG-CoA reductase inhibition and LDL receptor upregulation. They do NOT directly suppress hepatic VLDL production, which is regulated by: - Substrate availability (free fatty acids) - Hepatic insulin signalling (impaired in insulin resistance) - ApoB-100 availability - MTP (microsomal triglyceride transfer protein) activity ### Why Statin Monotherapy Fails for Triglycerides **Clinical Pearl:** In this patient: - **LDL-C response:** Good (220 → 140 mg/dL, 36% reduction) → LDL receptor upregulation is working - **TG response:** Poor (480 → 420 mg/dL, 12% reduction) → VLDL synthesis remains elevated The dissociation occurs because: 1. Statins upregulate LDL receptors → increased LDL clearance 2. But hepatic VLDL synthesis continues unabated due to: - Persistent insulin resistance - Elevated hepatic fatty acid influx from adipose tissue lipolysis - Uncontrolled hyperglycaemia (HbA1c 9.1%) ### Mechanism Table: Statin Effects on Lipoprotein Pathways | Pathway | Statin Effect | Result in This Patient | | --- | --- | --- | | HMG-CoA reductase | Inhibition | ↓ Cholesterol synthesis | | LDL receptor | Upregulation | ↓ LDL-C (good response) | | VLDL synthesis | No direct effect | ↑ VLDL persists (poor TG response) | | Hepatic fatty acid uptake | No effect | Continues (insulin resistance) | | Lipoprotein lipase | No effect | Normal activity, but overwhelmed by VLDL flux | ### Why Other Options Are Incorrect **Option 2 (Impaired LPL activity):** Lipoprotein lipase activity is typically normal or even elevated in diabetes due to compensatory upregulation. The problem is not LPL function but excessive VLDL substrate. **Option 3 (Statin-induced adipose lipolysis):** Statins do not inhibit HMG-CoA reductase in adipose tissue to a clinically significant degree; they are hepatotropic. Moreover, increased FFA mobilization would worsen, not explain, the triglyceride elevation. **Option 4 (ApoC-II inhibition):** Statins do not inhibit apoC-II synthesis. ApoC-II is a normal cofactor for lipoprotein lipase and is not rate-limiting in this scenario. ### Management Strategy **Mnemonic:** **TREAT-TG** = Triglycerides require: **T**hiazolidinediones (or GLP-1), **R**eduction of FFA (weight loss, glycaemic control), **E**zetimibe (modest TG ↓), **A**ddition of fibrate or icosapent ethyl, **T**arget HbA1c <7%, **T**ighten insulin sensitivity, **G**lucose control For this patient, optimal management includes: 1. **Intensify glycaemic control** (add GLP-1 agonist or SGLT2 inhibitor) → improves insulin sensitivity 2. **Add fibrate** (fenofibrate 145 mg daily) → reduces VLDL synthesis and increases LPL activity 3. **Weight loss** → reduces hepatic fatty acid influx 4. **Consider icosapent ethyl** (if TG remains 135–499 mg/dL after fibrate) [cite:Harrison 21e Ch 393; KD Tripathi 8e Ch 31]